Search

EHA Mentorship Program overview

Program goalsThe EHA Mentorship Program aims to:

Provide the early and mid-career European hematology community with access to mentorship that's relevant to their career stage
Expose hematologists and researchers from less professionally mobile backgrounds to career mentorship and best practices from other…

Read more

EHA Research Grant review and selection process

1. Eligibility checkAfter the deadline has passed, we'll check your application for completion and compliance with the eligibility criteria.

Read more

Lymphomas from A to Z

Nineteen countries from 3 continents were represented during the EHA-SWG Scientific Meeting on Rare Lymphomas on March 10-12, 2017 in Barcelona, Spain.

Read more

Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial

Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.

Read more

Appointment of new EHA Managing Director

The Hague (Netherlands), January 16, 2023. The European Hematology Association (EHA) is pleased to welcome its new Managing Director, Ignacio Quiles Lara, who took up the post on January 9.

Read more

Expert opinions for COVID-19 vaccination in patients with non-malignant hematologic diseases

Carlo Dufour, Helen Papadaki, Alan Warren, Colm Bradley, Cristina Mecucci, Jan Palmblad, Cornelia Zeidler, Francesca Fioredda, Sam Salek, Brigitte  Schlegelberger and Daniela Guardo, on behalf of the EHA SWG on Granulocytes and Constitutional Marrow Failure Disorders; Carlo L.

Read more

Registration & accommodation

Register here

Individual RegistrationRegistration fee includes:

Access to the scientific and educational sessions of the meeting. Digital meeting materials including the program and abstract book. Networking opportunities during breaks, receptions and dinners.

Read more

Restoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab

Hodgkin Lymphoma typically affects young men and women in their 30s. Although it is highly curable with the current combination of chemo and radiation therapy, approximately 20% of patients will not be cured with first line regimens.

Read more

Abstract & Case Report submission

Late-breaking case report submission is now closed.

Read more